Arguably, however, the most convincing data linking mutations in the THBD gene to disease manifestations have been in atypical hemolytic uremic syndrome, as a result of yet another function of thrombomodulin; namely, as a regulator of complement factor I-mediated inactivation of C3b. 9 Therefore, because of the "multitasking"
nature of thrombomodulin as a regulatory protein, it is important that any candidate thrombophilic mutations in the THBD gene be correlated not only with endothelial cellular expression, but also levels of circulating soluble thrombomodulin and activated protein C, and net plasma thrombin generation potential. Because the putative THBD-related regulatory genetic variants were ;3 times more common among populations of African descent compared with European populations, 1 these loci may contribute to inter-ethnic differences in VTE risk. Thus, confirmation of this finding in prospective cohort studies that include larger numbers of AAs with incidental VTE are critical. Also, because the susceptibility alleles are also present in whites (8% allele frequency), it will be important to assess the "generalizability" of this novel genetic VTE risk factor not only to Europeans, but also to other ethnic groups such as Hispanics who have both African and European ancestry. This study highlights the need to conduct genetic association studies of thrombotic outcomes in race/ethnic groups that are most burdened by the disease. Other genetic variation outside the well-established susceptibility loci identified in European studies may contribute to VTE risk in populations of African ancestry. Genetic association studies of quantitative intermediate traits or "endo-phenotypes" for VTE (such as D-dimer, factor VIII levels, or thrombingeneration potential) in large samples of underrepresented minority populations may also lead to the identification of additional genetic risk factors for VTE. The use of next-generation sequencing technologies (whole exome or whole genome sequencing) may uncover additional rare variants specific to African populations, which may help to explain disparities in VTE risk.
10 Equally intriguing will be the result of similar studies conducted in Asian American populations, where the risk of VTE appears to be significantly lower than in European and AA cohorts. 2 The recognition of genetic traits that protect against VTE may also lead to exploitable strategies for VTE prevention. As we enter the era of "Precision Medicine," the knowledge of VTE susceptibility alleles in individuals of African ancestry may ultimately provide important information to improve clinical care and reduce the high burden of disease in this population group. Conflict-of-interest disclosure: The authors declare no competing financial interests. n
